title: Comparison of vessel dilator and long-acting natriuretic peptide in the treatment of congestive heart failure.
abstract: BACKGROUND
  Long-acting natriuretic peptide (LANP; proANF 1-30) and vessel dilator (proANF 31-67) enhance sodium and water excretion in healthy human beings. The current investigation was designed to compare the beneficial effects of LANP and vessel dilator in persons with congestive heart failure (CHF).
  
  
  RESULTS
  LANP and vessel dilator (100 ng/kg body weight/min, respectively) were given intravenously for 60 minutes to subjects with New York Heart Association class III CHF (n = 17) while their urine volume and sodium and potassium excretion were monitored. Vessel dilator increased urine flow more than 5-fold, which was still increased (P <.001) 3 hours after stopping its infusion. Vessel dilator enhanced sodium excretion 3-fold in subjects with CHF (P <.01), which was still significantly (P <.01) elevated 3 hours after infusion. The effects of LANP were diminished, with urine flow only increasing 2-fold (P <.05). The fractional excretion of sodium increased maximally 6-fold secondary to vessel dilator and 3-fold with LANP. The CHF control patients had no changes in the above parameters. Part of the diminished response to LANP was found to be caused by its rapid decrease in the circulation of individuals with CHF.
  
  
  CONCLUSIONS
  These results indicate that vessel dilator has significant beneficial diuretic and natriuretic properties, which are not diminished, whereas the effects of LANP are diminished in human beings with CHF compared with healthy individuals.
authors.affiliation: Department of Medicine, James A. Haley Veterans Hospital, Tampa, FL 33612, USA.
authors.forename: D L
authors.initials: DL
authors.lastname: Vesely
authors.forename: J R
authors.initials: JR
authors.lastname: Dietz
authors.forename: J R
authors.initials: JR
authors.lastname: Parks
authors.forename: E A
authors.initials: EA
authors.lastname: Antwi
authors.forename: R M
authors.initials: RM
authors.lastname: Overton
authors.forename: M T
authors.initials: MT
authors.lastname: McCormick
authors.forename: G
authors.initials: G
authors.lastname: Cintron
authors.forename: D D
authors.initials: DD
authors.lastname: Schocken
mesh_terms: D009320:Atrial Natriuretic Factor / Q000008:administration & dosage / Q000627:therapeutic use*; D006333:Heart Failure / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D009318:Natriuresis / Q000187:drug effects*; D009994:Osmolar Concentration; D010446:Peptide Fragments / Q000008:administration & dosage / Q000627:therapeutic use*; D011498:Protein Precursors / Q000008:administration & dosage / Q000627:therapeutic use*; D013997:Time Factors
chemical_list: D010446:Peptide Fragments; D011498:Protein Precursors; C054547:atrial natriuretic factor prohormone (1-30), human; C054548:atrial natriuretic factor prohormone (31-67); D009320:Atrial Natriuretic Factor